Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Ask the Doctor: Updates on Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma

The Lymphoma Research Foundation’s (LRF) “Ask the Doctor About Lymphoma” programs are designed specifically for people affected by lymphoma. Tonight’s two-hour topic-specific seminar will feature a presentation led by Director of the CLL Research Center, Dr. Richard Furman. The presentation will be followed by a Q&A session. Online registration is available here. Program details are below:

Ask the Doctor: Updates on Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma

Richard R. Furman, MD
Associate Professor of Medicine
Director of the CLL Research Center
Weill Cornell Medical College
New York, NY
Follow Dr. Furman on Twitter

Date and Time
Tuesday, May 12, 2015
Networking: 6:00 PM
Program: 6:30 PM – 8:30 PM

Location
New York Marriott East Side
525 Lexington Ave at 49th Street
New York, NY 10017
www.marriott.com

Meals
Dinner will be provided for all registered attendees.

Program Overview – Online registration here

  • Overview and Treatment Options on CLL/SLL
  • Understanding Clinical Trials and Novel Therapies for CLL/SLL
  • Question and Answer Session

Registration Instructions
This program is offered free-of-charge to members of the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma community however, pre-registration is required. Please note: The names and phone numbers and/or email address for all attendees is required to complete the registration.

Three Easy Ways to Register!

Call: 800-500-9976
Email: mspellman@lymphoma.org
Web: Click here

FDA Grants Breakthrough Therapy Designation to Venetoclax for Patients with Relapsed/Refractory CLL with 17p Deletion

Earlier today the FDA granted the Breakthrough Therapy Designation to venetoclax (ABT-199). Venetoclax was awarded this designation for the treatment of relapsed or refractory CLL in previously treated patients with 17p deletion. Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein.

The Breakthrough Therapy Designation is intended to expedite the development and review of drugs for life-threatening conditions, based on preliminary clinical evidence. A full list of targeted treatments that have received FDA approval for the treatment of lymphoma can be found here.

Currently the Lymphoma Program has several phase 2 trials open to accrual for ABT-199 as a treatment for CLL patients. Dr. Richard Furman is the principal investigator for both trials:

Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-cell Receptor Signaling Pathway Inhibitor Therapy

Phase 2 Open-Label Study of the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion

A full listing of available CLL trials can be found here. Look to this space for more information regarding developments for the treatment of CLL.

REDLAMP 3: Bortezomib-Based Therapy for Newly Diagnosed Mantle Cell Lymphoma

In a recent publication from the New England Journal of Medicine researchers presented results from an investigation into whether the substitution of bortezomib for vincristine in R-CHOP improved patient outcomes for patients newly diagnosed with mantle cell lymphoma. Mantle cell lymphoma is an unusual lymphoma that engenders much debate as to what treatments should be used in patient care. In the below video Dr. John Leonard discusses the efficacy of substituting bortezomib for vincristine in R-CHOP and how this could improve the outcomes in patients with newly diagnosed mantle cell lymphoma.

You can follow Lymphoma Program Director John Leonard @JohnPLeonardMD.

The previous entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.